Viatris eye therapy fails to meet late-stage trial goal-June 2024-www.financetom.com

Viatris eye therapy fails to meet late-stage trial goal

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Viatris eye therapy fails to meet late-stage trial goal

Jul 18, 2025 4:24 AM

July 18 (Reuters) - Viatris ( VTRS ) said on Friday that

its experimental ophthalmic ointment did not meet the main goal

of a late-stage study in patients with an eye condition that

causes inflammation.

Previous page： Weave Communications Insider Sold Shares Worth $3,376,583, According to a Recent SEC Filing Next page： Tempus AI Insider Sold Shares Worth $13,278,632, According to a Recent SEC Filing

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Weave Communications Insider Sold Shares Worth $3,376,583, According to a Recent SEC Filing

Feb 3, 2025

03:14 AM EST, 02/03/2025 (MT Newswires) -- Blake G Modersitzki, Director, on January 29, 2025, sold 204,491 common shares in Weave Communications ( WEAV ) for $3,376,583. Following the Form 4 filing with the SEC, Modersitzki has control over a total of 999,333 shares of the company, with 111,097 shares held directly and 888,236 controlled indirectly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1609151/000141588925002615/xslF345X05/form4-02012025_120235.xml ...

Tempus AI Insider Sold Shares Worth $13,278,632, According to a Recent SEC Filing

Feb 3, 2025

03:10 AM EST, 02/03/2025 (MT Newswires) -- Eric P Lefkofsky, 10% Owner, Director, Chief Executive Officer and Chairman, on January 29, 2025, sold 238,800 Class A common shares in Tempus AI ( TEM ) for $13,278,632. Following the Form 4 filing with the SEC, Lefkofsky has control over a total of 48,757,318 shares of the company, with 5,532,987 shares held...

Alkermes Insider Sold Shares Worth $3,234,382, According to a Recent SEC Filing

Feb 3, 2025

03:12 AM EST, 02/03/2025 (MT Newswires) -- Craig C. Hopkinson, Executive Vice President, Research & Development, Chief Medical Officer, on January 30, 2025, sold 100,918 ordinary shares in Alkermes ( ALKS ) for $3,234,382. Following the Form 4 filing with the SEC, Hopkinson has control over a total of 44,290 shares of the company, with 44,290 shares held directly. SEC...

BRIEF-Arthur J. Gallagher & Co. Acquires W K Webster & Co Ltd

Feb 3, 2025

Feb 3 (Reuters) - Arthur J. Gallagher & Co. ( AJG ): * ARTHUR J. GALLAGHER & CO. ( AJG ) ACQUIRES W K WEBSTER & CO LTD * ARTHUR J. GALLAGHER & CO. ( AJG ): TERMS OF TRANSACTION WERE NOT DISCLOSED. Source text: Further company coverage: ...